NLRP3 and autoimmune polyendocrinopathy: Thus, pyroptosis-based treatment strategies might improve the therapeutic efficacy of APS, such as GSDMD, NLRP3 inflammasome, and caspase-1-related medicines (Figure 2 and Table 2).